We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Nyxoah Shares Rise on First U.S. Commercial Use of Genio System
Read MoreHide Full Article
Key Takeaways
Nyxoah launched U.S. commercialization of its Genio system after FDA approval for sleep apnea therapy.
The first U.S. patients have been implanted, highlighting strong surgeon enthusiasm and early payor support.
Expanding hospital approvals and training programs position Nyxoah for accelerating commercial momentum.
Nyxoah (NYXH - Free Report) has begun its U.S. commercial rollout of the Genio system, following FDA approval for its leadless, battery-free neurostimulation therapy for obstructive sleep apnea (OSA). The first commercialpatients have been successfully implanted with Genio, marking a pivotal step in bringing this innovative, minimally invasive solution to the U.S. market for OSA.
This milestone underscores strong early physician demand, growing payor coverage, including CMS, and a robust foundation for nationwide adoption. With trained surgeons, active patient pipelines, and expanding hospital approvals, Nyxoah is poised to drive sustained commercial momentum and reinforce its leadership in next-generation OSA treatment.
Likely Trend of the NYXH Stock Following the News
Following the announcement, shares of the company gained 17.2% at yesterday’s market closing. However, in the year-to-date period, NYXH’s shares have lost 27.5% against the industry’s 30.4% growth. The S&P 500 gained 15% in the same time frame.
The successful first U.S. commercial implants of Nyxoah’s Genio system mark the true start of its revenue ramp, transforming the company from a pre-commercial innovator into an active player in the U.S. sleep apnea market. Early physician enthusiasm, expanding reimbursement coverage, and streamlined hospital approvals suggest that procedure volumes are likely to accelerate ahead. As training programs scale and awareness grows, these dynamics are likely to drive recurring implant revenues and strengthen Nyxoah’s competitive position.
Meanwhile, NYXH currently has a market capitalization of $168.6 million. The company expects an earnings growth of 8.8% in 2026.
Image Source: Zacks Investment Research
Early U.S. Implants Signal Strong Market Readiness
The first successful U.S. commercial implants of Nyxoah’s Genio system are more than just a milestone; they are a validation of the company’s go-to-market readiness. Early data points, such as surgeon enthusiasm, rapid training uptake and smooth reimbursement approvals, suggest a well-coordinated commercial rollout. Surgeons are not only eager to adopt but are proactively lining up patients, reflecting confidence in both the procedure and patient outcomes.
With major payors like CMS already onboard and hospitals granting Value Analysis Committee approvals, Nyxoah is laying the groundwork for scalable adoption. This early traction could quickly translate into accelerating revenue as procedure volumes rise and clinical momentum builds.
Genio: A Differentiated Solution in Sleep Apnea Care
At the core of Nyxoah’s growth story is the Genio system, a battery-free, leadless neurostimulation device designed to treat OSA. Unlike traditional hypoglossal nerve stimulators that require invasive surgery and implanted batteries, Genio offers a streamlined, minimally invasive approach that activates both sides of the tongue for improved airway control. This bilateral stimulation not only simplifies the procedure but also enhances patient comfort and long-term compliance.
For investors, this technology represents a meaningful leap forward in the multi-billion-dollar sleep apnea market, where innovation and ease of use drive adoption. As more physicians experience the system’s efficiency and patients benefit from its simplicity, Genio has the potential to become a preferred therapy, positioning Nyxoah as a leading force in next-generation sleep care.
Favorable Industry Prospects for NYXH
Per a report by Grand View Research, the global sleep apnea devices market size was estimated at $4.5 billion in 2023 and is projected to reach $6.9 billion by 2030, registering a CAGR of 6.2% from 2024 to 2030.
The sleep apnea devices market is currently in a moderate growth stage, with an accelerating pace. This is driven by factors such as a growing geriatric population, a significant patient pool with sleep apnea, an increased prevalence of comorbidities linked to sleep apnea and the development of advanced devices.
NYXH’s Zacks Rank & Stocks to Consider
NYXH carries a Zacks Rank #4 (Sell) at present.
Some better-ranked stocks in the broader medical space are West Pharmaceutical Services, Inc. (WST - Free Report) , Medpace Holdings, Inc. (MEDP - Free Report) and Envista (NVST - Free Report) .
West Pharmaceutical reported second-quarter 2025 adjusted earnings per share (EPS) of $1.84, which beat the Zacks Consensus Estimate by 21.9%. Revenues of $766.5 million surpassed the consensus estimate by 5.4%. It currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
West Pharmaceutical has a long-term estimated growth rate of 8.5%. WST’s earnings surpassed estimates in each of the trailing four quarters, with an average surprise of 16.8%.
Medpace Holdings, sporting a Zacks Rank of 1, reported second-quarter 2025 EPS of $3.10, which beat the Zacks Consensus Estimate by 3.3%. Revenues of $603.3 million outpaced the consensus mark by 11.5%.
Medpace Holdings has a long-term estimated growth rate of 11.4%. MEDP’s earnings surpassed estimates in each of the trailing four quarters, with an average surprise of 13.9%.
Envista reported second-quarter 2025 adjusted EPS of 26 cents, which beat the Zacks Consensus Estimate by 8.3%. Revenues of $682 million surpassed the Zacks Consensus Estimate by 6.3%. It currently carries a Zacks Rank #2 (Buy).
Envista has a long-term estimated growth rate of 16.8%. NVST’s earnings surpassed estimates in each of the trailing four quarters, with an average surprise of 16.50%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Nyxoah Shares Rise on First U.S. Commercial Use of Genio System
Key Takeaways
Nyxoah (NYXH - Free Report) has begun its U.S. commercial rollout of the Genio system, following FDA approval for its leadless, battery-free neurostimulation therapy for obstructive sleep apnea (OSA). The first commercialpatients have been successfully implanted with Genio, marking a pivotal step in bringing this innovative, minimally invasive solution to the U.S. market for OSA.
This milestone underscores strong early physician demand, growing payor coverage, including CMS, and a robust foundation for nationwide adoption. With trained surgeons, active patient pipelines, and expanding hospital approvals, Nyxoah is poised to drive sustained commercial momentum and reinforce its leadership in next-generation OSA treatment.
Likely Trend of the NYXH Stock Following the News
Following the announcement, shares of the company gained 17.2% at yesterday’s market closing. However, in the year-to-date period, NYXH’s shares have lost 27.5% against the industry’s 30.4% growth. The S&P 500 gained 15% in the same time frame.
The successful first U.S. commercial implants of Nyxoah’s Genio system mark the true start of its revenue ramp, transforming the company from a pre-commercial innovator into an active player in the U.S. sleep apnea market. Early physician enthusiasm, expanding reimbursement coverage, and streamlined hospital approvals suggest that procedure volumes are likely to accelerate ahead. As training programs scale and awareness grows, these dynamics are likely to drive recurring implant revenues and strengthen Nyxoah’s competitive position.
Meanwhile, NYXH currently has a market capitalization of $168.6 million. The company expects an earnings growth of 8.8% in 2026.
Image Source: Zacks Investment Research
Early U.S. Implants Signal Strong Market Readiness
The first successful U.S. commercial implants of Nyxoah’s Genio system are more than just a milestone; they are a validation of the company’s go-to-market readiness. Early data points, such as surgeon enthusiasm, rapid training uptake and smooth reimbursement approvals, suggest a well-coordinated commercial rollout. Surgeons are not only eager to adopt but are proactively lining up patients, reflecting confidence in both the procedure and patient outcomes.
With major payors like CMS already onboard and hospitals granting Value Analysis Committee approvals, Nyxoah is laying the groundwork for scalable adoption. This early traction could quickly translate into accelerating revenue as procedure volumes rise and clinical momentum builds.
Genio: A Differentiated Solution in Sleep Apnea Care
At the core of Nyxoah’s growth story is the Genio system, a battery-free, leadless neurostimulation device designed to treat OSA. Unlike traditional hypoglossal nerve stimulators that require invasive surgery and implanted batteries, Genio offers a streamlined, minimally invasive approach that activates both sides of the tongue for improved airway control. This bilateral stimulation not only simplifies the procedure but also enhances patient comfort and long-term compliance.
For investors, this technology represents a meaningful leap forward in the multi-billion-dollar sleep apnea market, where innovation and ease of use drive adoption. As more physicians experience the system’s efficiency and patients benefit from its simplicity, Genio has the potential to become a preferred therapy, positioning Nyxoah as a leading force in next-generation sleep care.
Favorable Industry Prospects for NYXH
Per a report by Grand View Research, the global sleep apnea devices market size was estimated at $4.5 billion in 2023 and is projected to reach $6.9 billion by 2030, registering a CAGR of 6.2% from 2024 to 2030.
The sleep apnea devices market is currently in a moderate growth stage, with an accelerating pace. This is driven by factors such as a growing geriatric population, a significant patient pool with sleep apnea, an increased prevalence of comorbidities linked to sleep apnea and the development of advanced devices.
NYXH’s Zacks Rank & Stocks to Consider
NYXH carries a Zacks Rank #4 (Sell) at present.
Some better-ranked stocks in the broader medical space are West Pharmaceutical Services, Inc. (WST - Free Report) , Medpace Holdings, Inc. (MEDP - Free Report) and Envista (NVST - Free Report) .
West Pharmaceutical reported second-quarter 2025 adjusted earnings per share (EPS) of $1.84, which beat the Zacks Consensus Estimate by 21.9%. Revenues of $766.5 million surpassed the consensus estimate by 5.4%. It currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
West Pharmaceutical has a long-term estimated growth rate of 8.5%. WST’s earnings surpassed estimates in each of the trailing four quarters, with an average surprise of 16.8%.
Medpace Holdings, sporting a Zacks Rank of 1, reported second-quarter 2025 EPS of $3.10, which beat the Zacks Consensus Estimate by 3.3%. Revenues of $603.3 million outpaced the consensus mark by 11.5%.
Medpace Holdings has a long-term estimated growth rate of 11.4%. MEDP’s earnings surpassed estimates in each of the trailing four quarters, with an average surprise of 13.9%.
Envista reported second-quarter 2025 adjusted EPS of 26 cents, which beat the Zacks Consensus Estimate by 8.3%. Revenues of $682 million surpassed the Zacks Consensus Estimate by 6.3%. It currently carries a Zacks Rank #2 (Buy).
Envista has a long-term estimated growth rate of 16.8%. NVST’s earnings surpassed estimates in each of the trailing four quarters, with an average surprise of 16.50%.